Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Susan O’Brien et al.|New England Journal of Medicine|2015Cited by 890
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency ProfileTjeerd Barf, Allard Kaptein|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 366